MedDay’s Phase 3 Trial - impact on Optic Neuritis failed

A board to discuss future MS therapies in early stage (Phase I or II) trials.

MedDay’s Phase 3 Trial - impact on Optic Neuritis failed

Postby ElliotB » Wed Sep 20, 2017 3:40 pm

I just saw this even though it is from a few months ago - hope it is not a duplication on TIMS.

MedDay’s MD-1003 PHASE III Optic Neuritis Trial Results For MS


A clinical trial of MedDay’s promising medication MD-1003 in a study of the drugs impact on Optic Neuritis failed to meet its endpoint in outperforming placebo towards improving vision for people who have multiple sclerosis.

Here is a link to the article (from May 10, 2017 ):

http://www.msunites.com/meddays-md-1003 ... ts-for-ms/



On a positive note, they are reporting positive results for patients with Progressive Multiple Sclerosis (although only 12.6% of patients taking MD1003 (biotin) had an improvement in their EDSS score.)
ElliotB
Family Elder
 
Posts: 1232
Joined: Mon Feb 03, 2014 4:08 pm

Advertisement

Re: MedDay’s Phase 3 Trial - impact on Optic Neuritis failed

Postby Marc70 » Thu Sep 21, 2017 11:24 am

Dude,

Where do you get your stuff from? This is like 1 1/2 years old....

http://www.medday-pharma.com/news-and-e ... is-at-aan/
Marc70
Newbie
 
Posts: 8
Joined: Thu Oct 29, 2015 1:19 pm


Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service